(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London closed lower on Wednesday, as investors anxiously look ahead to this evening's Federal Open Market Committee meeting minutes. Read More
(Alliance News) - Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was overshadowed by a mistake in the company's previous prescription forecasts. Read More
Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financial officer, effective next Tuesday. He replaces Hans-Peter Rudolf, who left Shield in October to pursue new opportunities. Shanbhag was previously CFO of Nasdaq-listed Akili Inc, which he "helped transform...from a private to a public entity". Before this, he held various senior finance leadership roles at Vertex Pharmaceuticals Inc, including as Head of International Finance & Accounting. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Shield Therapeutics PLC - commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Chief Financial Officer Hans-Peter Rudolf will leave the company next week Friday to pursue other opportunities. The firm's company controller, Paul Spoors, will take on the CFO role on an interim basis. Shield says it has engaged an executive search firm to identify a new CFO. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Shield Therapeutics PLC on Tuesday said it has now completed its USD20 million senior secured debt facility from SWK Funding LLC. Read More
(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023. Read More
(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023. Read More
Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Says it will change reporting currency to US dollars from pound sterling from 2023 results. Says the interim results for the first half of 2023 will include condensed and consolidated US dollar financial information for the period and full-year 2022. Read More
(Correcting the name of Sage Therapeutics Inc. Please ignore incorrect coding of Shield Therapeutics PLC.) Read More
(Alliance News) - The US Food & Drug Administration has approved Zurzuvae, zuranolone, 50 mg for adults with postpartum depression, Sage Therapeutics PLC and Biogen Inc said in a statement. Read More
Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Sees strong prescription growth in the second quarter and first half of 2023. Total prescriptions for second quarter increase 50% to 15,800 compared to the first quarter. In first half of 2023, total prescriptions grow to around 26,300 which exceeds total prescription volumes for all of 2022. The company says that this growth in the first half means Shield is likely to meet its 2023 goal for US Accrufer prescriptions. Read More